Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Basic) (2019 - 2025)

Goldenwell Biotech filings provide 7 years of EPS (Basic) readings, the most recent being -$0.0 for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 66.28% to -$0.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.0, a 162.16% decrease, with the full-year FY2024 number at -$0.0, down 9.14% from a year prior.
  • EPS (Basic) hit -$0.0 in Q3 2025 for Goldenwell Biotech, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.0 in Q4 2024 to a low of -$0.01 in Q4 2022.
  • Median EPS (Basic) over the past 5 years was -$0.0 (2024), compared with a mean of -$0.0.
  • Biggest five-year swings in EPS (Basic): plummeted 14209.11% in 2021 and later skyrocketed 418.3% in 2024.
  • Goldenwell Biotech's EPS (Basic) stood at -$0.0 in 2021, then tumbled by 2849.02% to -$0.01 in 2022, then skyrocketed by 97.74% to -$0.0 in 2023, then skyrocketed by 418.3% to $0.0 in 2024, then crashed by 111.75% to -$0.0 in 2025.
  • The last three reported values for EPS (Basic) were -$0.0 (Q3 2025), -$0.0 (Q2 2025), and -$0.0 (Q1 2025) per Business Quant data.